Opinion|Videos|April 30, 2025
Effect of Hypercortisolism on Cardiovascular and Diabetes Care
Experts discuss how hypercortisolism contributes to treatment-resistant hypertension and other cardiovascular diseases, the impact of treating hypercortisolism on cardiovascular risks, when cardiologists should suspect hypercortisolism as a contributing factor to cardiovascular disease, the role of hypercortisolism in type 2 diabetes, how it complicates the management of type 2 diabetes and impacts long-term glucose control, and when endocrinologists should suspect hypercortisolism in their patients with type 2 diabetes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does hypercortisolism contribute to treatment-resistant hypertension and other cardiovascular diseases?
- We have mentioned that there are cardiovascular risks associated with hypercortisolism. How does treatment of hypercortisolism impact these risks?
- Looking specifically from a cardiology perspective, when should a cardiologist suspect hypercortisolism as a contributing factor to cardiovascular disease?
- What is the role of hypercortisolism in type 2 diabetes?
- How does hypercortisolism complicate the management of type 2 diabetes, and how does it impact long-term glucose control?
- Now, let us shift to the endocrinology perspective. When should an endocrinologist suspect hypercortisolism in their patients with type 2 diabetes?
Advertisement
Related to this article
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data
5